Becton, Dickinson and Co. | BDX - Cost Of Sales

Stock Price
149.52
Daily Change
-0.70 -0.47%
Monthly
-3.34%
Yearly
-27.57%
Q2 Forecast
148.88

Becton, Dickinson and Co. reported $2.84B in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Abbott USD 5.3B 380M Mar/2026
Agilent USD 852M 19M Dec/2025
Align Technology USD 363.97M 7.48M Dec/2025
AngioDynamics USD 37.29M 786K Sep/2025
Avanos Medical USD 94.9M 3.1M Dec/2025
Baxter International USD 2.4B 512M Dec/2025
Becton, Dickinson and Co. USD 2.84B 2.35B Dec/2025
Bio-Rad Laboratories USD 309.6M 3.3M Sep/2025
Boston Scientific USD 1.83B 8M Mar/2026
Cooper Companies USD 376.8M 87.4M Dec/2025
Danaher USD 2.36B 512M Mar/2026
Dentsply International USD 518M 55M Dec/2025
Dexcom USD 466.9M 11M Dec/2025
Edwards Lifesciences USD 362.6M 19.6M Mar/2026
Globus Medical USD 290.47M 8.09M Dec/2025
Insulet USD 215.2M 19M Dec/2025
Integra LifeSciences USD 193.44M 1.62M Dec/2025
Intuitive Surgical USD 940.3M 21.6M Mar/2026
J&J USD 8.07B 103M Mar/2026
Masimo USD 165.2M 24.3M Dec/2025
Medtronic USD 3.61B 83M Dec/2025
Solventum Corp USD 971M 8M Dec/2025
Stryker USD 2.69B 373M Dec/2025
Tandem Diabetes Care USD 122.92M 7.96M Dec/2025
Teleflex USD 261.54M 199.84M Dec/2025
Terumo JPY 143.44B 15.47B Dec/2025
Thermo Fisher Scientific USD 6.96B 620M Mar/2026
Zimmer Biomet Holdings USD 970.1M 234.3M Dec/2025